• HOME
  • R&D
  • MA-B2/MO-B2

Development of treatment
for patients

MA-B2/MO-B2

MA-B2

Development of MA-B2,
an antibody therapeutic targeting BAG2

First Discovery of BAG2 Target Protein

  • Plays a role in deactivating immune cell activity
  • In various cancers, a large amount of BAG2 is secreted into the blood when cancer recurs or metastasizes

Development Roadmap of BAG2 Therapeutic and Diagnostic

  • Antibody therapeutic
    MA-B2
  • Diagnostic Kit
    MO-B2
  • Cancer metastasis / relapse predictive biomarker
  • Companion diagnostic development to propose optimal treatment method and confirm response rates

Mechanism of Action of Antibody Therapeutic (MA-B2)

During carcinogenesis, MA-B2 inhibits the metastatic activity of cathepsin B, an enzyme involved in cancer metastasis, and activates the immune system by blocking the immune activity inhibitory effect of BAG2 protein.

MO-B2

Early approval expected as MO-B2 will be the first diagnostic that predicts metastasis and recurrence of triple-negative breast cancer

BAG2 is specifically secreted into the serums of patients with aggressive breast cancer

Sandwich ELISA

ELISA analysis showing BAG2 protein levels in the serums of breast cancer patients

Kaplan-Meier

Kaplan-Meier analysis showing recurrence-free survival depending on secreted BAG2 protein level in patients with breast caner

US FDA Recommendation to couple drug development with diagnostics

  • RT-PCR

    YoY Revenue Growth: $254m USD (2017) →
    $299m USD (2018) *17.7% 증가

    Oncotype Dx (ER+, HER2-)

  • HercepTest Kits

    Agilent acquired Dako for
    $2.2b USD (2010)

    HercepTest (HER2+)

  • MO-B2 (BAG2 Kits)

    Diagnosis of cancer metastasis and recurrence
    as well as biomarker-based companion diagnostic kit

    MO-B2 : ER-, PR-, HER2- (Triple Negative)